MSTN and Cirrhosis: In our study of 198 patients with cirrhosis, for the entire cohort, the 1-, 3-, and 5-year cumulative overall survival (OS) rates were 93.9%, 72.7%, and 50.4%, respectively, in the higher myostatin group, and 97.0%, 83.3%, and 73.6%, respectively, in the lower myostatin group (p = 0.0001).